Oncology

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Lenvatinib (Lenvima) has been granted approval by the FDA as a first-line treatment for patients with unresectable hepatocellular carcinoma.

Surviving cancer during childhood can lead to health problems and depression later in life.

A liquid biopsy test examines circulating tumor cells in blood samples of patients with prostate cancer to determine how they will respond to certain therapies.

Researchers have developed a novel peptide drug called FFW that could potentially reduce tumor growth and slow progression of liver cancer.

Patients who were more satisfied with the communication they received from cancer care providers often had better health outcomes at lower costs.

Researchers have developed a novel peptide drug that has the potential to reduce tumor growth and slow down the spread of cancer cells.

Globally, lung cancer mortality rates among women are projected to increase by 43% from 2015 to 2030.

The annual cost of treating cancer is projected to rise to $173 billion by 2020, a 39% increase since 2010.

Combination of Lenvima and Keytruda awarded second Breakthrough Therapy designation for the treatment of endometrial carcinoma.

Advancements in breast cancer treatment have improved survival rates, but financial hardships related to the cost of these lifesaving therapies can weigh heavily on patients.

Survey findings indicate that patients with breast cancer worry about financial hardships related to their treatment, yet many do not feel providers adequately address these concerns.

Study investigates complementary medicine use in patients with curable cancer types and its impact on survival and adherence to conventional therapy.

Top news of the day from across the health care landscape.

A recent systematic review and meta-analysis found that men with advanced cancers respond better than women to treatment with anti-PD-1 or anti-CTLA-4 immune checkpoint inhibitors.

The approval of ivosidenib fills an unmet need for patients with relapsed or refractory acute myeloid leukemia who have an IDH1 genetic mutation.

Genentech announced that the FDA has granted Breakthrough Therapy Designation to atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) as a first-line treatment for patients with the most common form of liver cancer.

This is the first approval that the FDA has granted as part of its new approaches to streamlining the development and review of oncology drugs.

Approximately 80% of manufacturers are already managing their products, many of which are oncology drugs, through a limited distribution model.

The discovery may pave the way for the development of personalized medicine in order to target this newly discovered form of the disease.

Enzalutamide (Xtandi) is the first and only FDA-approved oral medication for both non-metastatic and metastatic castration-resistant prostate cancer.

With this new indication, enzalutamide is the first and only FDA-approved oral medication for both non-metastatic and metastatic CRPC.

A look at last week's top stories in the world of pharmacy.

Nivolumab (Opdivo) plus ipilimumab (Yervoy) approved for patients with microsatellite instability high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

Hepatocellular carcinoma is the most common type of liver cancer in adults.

Approvals and indications of this drug were based on 3 main clinical trials.

New research identified predictors of long-term survival and health-related quality of life in patients with newly diagnosed multiple myeloma.

In the phase 3 PALOMA-3 trial, Pfizer’s palbociclib (Ibrance) narrowly missed reaching its secondary endpoint of overall survival (OS), according to a press release.